# SHIP

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ship

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.immune-path.com
- Latest round: Series A (Nov 29, 2018)
- Investors on record: 2

## About

Established in 2017 and based in Suzhou, China, SHIP is a biotechnology company that focuses on the research and development of vaccines and biomedical products. The consulting team has over 20 years of experience in innovative vaccine basic research. In November 2018, SHIP closed a series A funding. In 2021, the industrial base was in construction. In 2023, the Phase III clinical trial of YD101 was started.


The company is committed to the development and industrialization of innovative human vaccines and biopharmaceutical products and has developed five R&D technology platforms such as recombinant protein antigen vaccine, peptide polysaccharide conjugate vaccine, and so on. The company's pipeline includes more than ten preventive and therapeutic vaccine products which cover children's vaccines and adult vaccines.

## Funding rounds

- Series A, Nov 29, 2018 — NLVC, Lilly Asia Ventures

## Investors

- NLVC (https://capitalatlas.ai/funds/nlvc) — Series A
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A